Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Innate Pharma (IPHYF) over the last 8 years, with Q2 2025 value amounting to -$25.6 million.

  • Innate Pharma's Net Income towards Common Stockholders rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$171.8 million, marking a year-over-year decrease of 2034.05%. This contributed to the annual value of -$9.4 million for FY2024, which is 8309.53% up from last year.
  • As of Q2 2025, Innate Pharma's Net Income towards Common Stockholders stood at -$25.6 million, which was up 193.0% from -$58.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Net Income towards Common Stockholders ranged from a high of $7.5 million in Q2 2021 and a low of -$131.3 million during Q4 2021
  • Over the past 5 years, Innate Pharma's median Net Income towards Common Stockholders value was -$26.1 million (recorded in 2024), while the average stood at -$38.9 million.
  • In the last 5 years, Innate Pharma's Net Income towards Common Stockholders surged by 89402.78% in 2023 and then plummeted by 432199.99% in 2024.
  • Over the past 5 years, Innate Pharma's Net Income towards Common Stockholders (Quarter) stood at -$131.3 million in 2021, then surged by 57.92% to -$55.2 million in 2022, then decreased by 12.25% to -$62.0 million in 2023, then increased by 6.38% to -$58.1 million in 2024, then soared by 55.89% to -$25.6 million in 2025.
  • Its last three reported values are -$25.6 million in Q2 2025, -$58.1 million for Q4 2024, and -$26.1 million during Q2 2024.